- Home
- BSLK vs BLRX Comparison
BSLK vs BLRX Comparison
Compare BSLK & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSLK
- BLRX
- Stock Information
- Founded
- BSLK 2009
- BLRX 2003
- Country
- BSLK United States
- BLRX Israel
- Employees
- BSLK N/A
- BLRX N/A
- Industry
- BSLK
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BSLK
- BLRX Health Care
- Exchange
- BSLK NYSE
- BLRX Nasdaq
- Market Cap
- BSLK 12.3M
- BLRX 10.3M
- IPO Year
- BSLK N/A
- BLRX 2011
- Fundamental
- Price
- BSLK $6.10
- BLRX $3.00
- Analyst Decision
- BSLK
- BLRX Buy
- Analyst Count
- BSLK 0
- BLRX 2
- Target Price
- BSLK N/A
- BLRX $26.00
- AVG Volume (30 Days)
- BSLK 47.1K
- BLRX 30.5K
- Earning Date
- BSLK 05-21-2025
- BLRX 05-27-2025
- Dividend Yield
- BSLK N/A
- BLRX N/A
- EPS Growth
- BSLK N/A
- BLRX N/A
- EPS
- BSLK N/A
- BLRX N/A
- Revenue
- BSLK $1,373,000.00
- BLRX $28,940,000.00
- Revenue This Year
- BSLK N/A
- BLRX N/A
- Revenue Next Year
- BSLK N/A
- BLRX N/A
- P/E Ratio
- BSLK N/A
- BLRX N/A
- Revenue Growth
- BSLK N/A
- BLRX 502.92
- 52 Week Low
- BSLK $4.54
- BLRX $2.30
- 52 Week High
- BSLK $340.40
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- BSLK N/A
- BLRX 50.42
- Support Level
- BSLK N/A
- BLRX $2.30
- Resistance Level
- BSLK N/A
- BLRX $3.09
- Average True Range (ATR)
- BSLK 0.00
- BLRX 0.23
- MACD
- BSLK 0.00
- BLRX 0.06
- Stochastic Oscillator
- BSLK 0.00
- BLRX 88.87
About BSLK BOLT PROJECTS HOLDINGS INC
Bolt Projects Holdings Inc formerly Golden Arrow Merger Corp is an shell company.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.